Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Wound care firm gets $25m series B and new CEO:

This article was originally published in Clinica

  • News

Executive Summary

PolyRemedy, an Irvine, California company developing a system that can fabricate wound dressings at point of care, has clinched $25m in new capital. Co-leading the series B round were Advanced Technology Ventures (ATV) and IDG Ventures. Other investors that took part in the financing included Harris & Harris Group and existing PolyRemedy shareholder Medventure Associates. In conjunction with the investment, Tom Rodgers from ATV and Michael Greeley from IDG Ventures join the company as board directors. PolyRemedy's robotic system is designed to produce customised, pre-assembled wound dressings at the point of care. The dressings, based on a nano-material, are intended for use on chronic wounds such as diabetic ulcers.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT046129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By